Clinical Trials for Madan Jagasia

11 Open Trials

Trial TypeProtocol No. &
Open Date
Summary
Basic ScienceVICCBMT1063
07/27/2011
T-Regulatory Homing Subsets as a Predictor of Response in GVHD Treated with Extracorporeal Photopheresis
OtherVICCBMT1380
02/05/2014
Chronic GVHD Response Measures Validation
Supportive CareVICCBMT1335
02/18/2014
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Protective Efficacy and Safety of a Therapeutic Vaccine, ASP01113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)
Supportive CareVICCBMT12104
02/04/2014
Phase I Trial of Brentuximab Vedotin for Steroid Refractory Acute Graft-vs.-Host Disease (GVHD)
Supportive CareVICCBMT1218
09/04/2012
A Randomized, Prospective, Double Blind, Placebo-Controlled, Phase 3 Study of US-ATG-F Prophylaxis as a Supplement to Standard of Care Prophylaxis to Prevent Moderate to Severe Chronic GVHD in Adult Acute Myeloid Leukemia, Acute Lymphoid Leukemia, and Myelodysplastic Syndrome Patients after Allogeneic Stem Cell Transplantation from Unrelated Donors
TreatmentVICCHEM1319
08/07/2013
A Phase 3, Randomized, Open Label Trial of Lenalidomide/dexamethasone With or Without Elotuzumab in Subjects with Previously Untreated Multiple Myeloma
TreatmentVICCHEM12107
03/31/2013
A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide (POM), Bortezomib (BTZ) and Low-Dose Dexamethasone (LD-DEX) versus Bortezomib and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma (MM)
TreatmentVICCBMT1148
05/11/2012
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis after Allogeneic Hematopoietic Cell Transplantation (Consortium)
TreatmentVICCBMT1129
11/17/2011
A Randomized Controlled Study of Extracorporeal Photopheresis (ECP) Therapy with UVADEX for the Treatment of Patients with Moderate to Severe Chronic Graft vs Host Disease
TreatmentVICCBMT1071
08/01/2011
Targeted Therapy for Bronchiolitis Obliterans Syndrome (BOS)
TreatmentVICCBMT1020
11/15/2010
Impact of First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment with Velcade Based Therapy

Back to Find By Doctor

You do not have JavaScript enabled. This site works better with JavaScript turned on.